Weight and Lean Body Mass Change with Antiretroviral Initiation and Impact on Bone Mineral Density: AIDS Clinical Trials Group Study A5224s

類似資料

• Impact of Randomized Antiretroviral Therapy Initiation on Glucose Metabolism: AIDS Clinical Trials Group Study A5224s
  著者:: ERLANDSON, Kristine Mace, 等
  出版事項: (2014)
• Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202
  著者:: McComsey, Grace A., 等
  出版事項: (2011)
• Associations of Inflammatory Markers with AIDS and non-AIDS Clinical Events after Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202
  著者:: McComsey, Grace A, 等
  出版事項: (2014)
• Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s
  著者:: McComsey, Grace A., 等
  出版事項: (2011)
• Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir: ACTG A5224 s, A5202 substudy
  著者:: McComsey, Grace A., 等
  出版事項: (2012)